You sat across from your oncologist expecting the next treatment plan, and instead heard the words "there's nothing more we can do." The floor drops out.

Relapsed multiple myeloma demands treatment decisions grounded in current cytogenetic risk profiles, prior therapy history, and access to novel agents. A second opinion helps clarify next-line therapy eligibility and investigational pathways. Key Takeaways Symptomatic relapse with organ damage requires urgent specialist review, while asymptomatic M-protein rise allows scheduled consultations over weeks. Prepare four core documents before consultation: pathology report with FI